AT395375B - Immunglobulinkonjugate, verfahren zu deren herstellung und anwendung sowie pharmazeutische mittel, die diese enthalten - Google Patents

Immunglobulinkonjugate, verfahren zu deren herstellung und anwendung sowie pharmazeutische mittel, die diese enthalten Download PDF

Info

Publication number
AT395375B
AT395375B AT0067488A AT67488A AT395375B AT 395375 B AT395375 B AT 395375B AT 0067488 A AT0067488 A AT 0067488A AT 67488 A AT67488 A AT 67488A AT 395375 B AT395375 B AT 395375B
Authority
AT
Austria
Prior art keywords
ida
cells
mice
antibody
conjugates
Prior art date
Application number
AT0067488A
Other languages
German (de)
English (en)
Other versions
ATA67488A (de
Original Assignee
Erba Carlo Spa
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa, Univ Melbourne filed Critical Erba Carlo Spa
Publication of ATA67488A publication Critical patent/ATA67488A/de
Application granted granted Critical
Publication of AT395375B publication Critical patent/AT395375B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0067488A 1987-03-11 1988-03-11 Immunglobulinkonjugate, verfahren zu deren herstellung und anwendung sowie pharmazeutische mittel, die diese enthalten AT395375B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPI080387 1987-03-11
AUPI295587 1987-07-07

Publications (2)

Publication Number Publication Date
ATA67488A ATA67488A (de) 1992-05-15
AT395375B true AT395375B (de) 1992-12-10

Family

ID=25643244

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0067488A AT395375B (de) 1987-03-11 1988-03-11 Immunglobulinkonjugate, verfahren zu deren herstellung und anwendung sowie pharmazeutische mittel, die diese enthalten

Country Status (29)

Country Link
US (1) US5798097A ( )
JP (1) JP2736255B2 ( )
KR (1) KR0130906B1 ( )
CN (1) CN1045621C ( )
AT (1) AT395375B ( )
AU (1) AU622105B2 ( )
BE (1) BE1001051A4 ( )
CA (1) CA1329156C ( )
CH (1) CH678815A5 ( )
CZ (1) CZ161288A3 ( )
DE (1) DE3808166C2 ( )
DK (1) DK173792B1 ( )
ES (1) ES2006109A6 ( )
FI (1) FI98706C ( )
FR (1) FR2612074B1 ( )
GB (1) GB2203154B ( )
GR (1) GR1000059B ( )
HU (1) HU205266B ( )
IE (1) IE64781B1 ( )
IL (1) IL85688A0 ( )
IT (1) IT8819746A0 ( )
MY (1) MY103231A ( )
NL (1) NL8800610A ( )
NO (1) NO178954C ( )
NZ (1) NZ223834A ( )
PT (1) PT86960B ( )
RU (1) RU2106147C1 ( )
SE (1) SE503402C2 ( )
YU (1) YU46858B ( )

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
DK1119371T3 (da) * 1998-10-09 2011-03-07 Vegenics Ltd Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
WO2004094647A2 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2014124487A1 (en) 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT342035B (de) * 1975-01-22 1978-03-10 Farmaceutici Italia Verfahren zur optischen trennung von racemischem 1,4-dimethoxy-6-hydroxy-6-acetyltetralin
AT343811B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT343812B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
AT346838B (de) * 1975-01-22 1978-11-27 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1511680A (en) 1975-11-18 1978-05-24 Farmaceutici Italia Daunosaminyl anthracyclinones
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
GB8413464D0 (en) * 1984-05-25 1984-07-04 Erba Farmitalia Anthracycline-anionic polymer conjugates
JPS61155334A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT342035B (de) * 1975-01-22 1978-03-10 Farmaceutici Italia Verfahren zur optischen trennung von racemischem 1,4-dimethoxy-6-hydroxy-6-acetyltetralin
AT343811B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
AT343812B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
AT346838B (de) * 1975-01-22 1978-11-27 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance

Also Published As

Publication number Publication date
GB8805865D0 (en) 1988-04-13
FR2612074B1 (fr) 1991-06-21
CA1329156C (en) 1994-05-03
JPS63301832A (ja) 1988-12-08
AU1288188A (en) 1988-09-15
DK173792B1 (da) 2001-11-05
DE3808166A1 (de) 1988-09-22
DK131588A (da) 1988-09-12
AU622105B2 (en) 1992-04-02
NO178954C (no) 1996-07-10
FI881158A0 (fi) 1988-03-11
KR0130906B1 (ko) 1998-04-23
IL85688A0 (en) 1988-08-31
FR2612074A1 (fr) 1988-09-16
US5798097A (en) 1998-08-25
ATA67488A (de) 1992-05-15
KR880010775A (ko) 1988-10-24
SE8800886D0 (sv) 1988-03-11
IE64781B1 (en) 1995-09-06
IE880701L (en) 1988-09-11
DE3808166C2 (de) 1997-08-28
NO881105L (no) 1988-09-12
JP2736255B2 (ja) 1998-04-02
NL8800610A (nl) 1988-10-03
SE8800886L (sv) 1989-09-12
HU205266B (en) 1992-04-28
NL195078C ( ) 2003-07-30
HUT46547A (en) 1988-11-28
SE503402C2 (sv) 1996-06-10
CZ281193B6 (cs) 1996-07-17
FI881158A (fi) 1988-09-12
GR880100148A (en) 1989-01-31
GB2203154A (en) 1988-10-12
FI98706B (fi) 1997-04-30
CN1045621C (zh) 1999-10-13
RU2106147C1 (ru) 1998-03-10
NZ223834A (en) 1990-05-28
ES2006109A6 (es) 1989-04-01
FI98706C (fi) 1997-08-11
YU48288A (en) 1989-08-31
PT86960B (pt) 1992-06-30
NO178954B (no) 1996-04-01
GB2203154B (en) 1991-06-26
NO881105D0 (no) 1988-03-11
YU46858B (sh) 1994-06-24
MY103231A (en) 1993-05-29
PT86960A (pt) 1988-04-01
BE1001051A4 (fr) 1989-06-20
GR1000059B (el) 1990-06-27
IT8819746A0 (it) 1988-03-11
CN88101810A (zh) 1988-11-09
CH678815A5 ( ) 1991-11-15
CZ161288A3 (en) 1996-07-17
DK131588D0 (da) 1988-03-11

Similar Documents

Publication Publication Date Title
DE68912232T2 (de) Konjugate zytotoxischer Arzneimittel.
DE68915179T2 (de) Anthracyclin-Immunokonjugate mit neuem Spacer und Verfahren zu deren Herstellung.
DE3784720T2 (de) Produkt, praeparat und methode zum bekaempfen der allergien.
DE3685625T2 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
DE69005352T2 (de) Antikörper enthaltende Verabreichungssysteme für biologische verhaltensändernde Stoffe.
DE3689071T2 (de) Immunheilbehandlung.
DE69838953T2 (de) Methoden zur herstellung von glykosylierten antikörpern und antikörperfragmenten mit reaktiven ketongruppen
CH655010A5 (de) Pharmazeutischer wirkstoff mit antitumoraktivitaet.
DE2623736A1 (de) Antitumormittel und verfahren zu dessen herstellung
DE68927610T2 (de) Antikörper-Arzneimittel Konjugale
DE69030213T2 (de) Anthracyclin-Konjugate mit einem neuen Linker und Verfahren zu dessen Herstellung
DE69012747T2 (de) Polymyxinkonjugate.
AT395375B (de) Immunglobulinkonjugate, verfahren zu deren herstellung und anwendung sowie pharmazeutische mittel, die diese enthalten
DE69019959T2 (de) Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
Pietersz et al. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates
DE69028320T2 (de) Illudin-analoge, verwendet als antitumormittel
DE68907430T2 (de) Cytotoxische therapie.
DE3689299T2 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
DE69026387T2 (de) Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
EP1466614B1 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
DE69026812T2 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
DE4205938A1 (de) Immunotoxine
EP1732611A1 (de) Herstellung und verwendung des konjugats methotrexat-albumin als mittel zur immunsuppression bei gvhd
DE3786334T2 (de) -i(D)-GL-KONJUGATTHERAPIE.
DE69215407T2 (de) Monoklonale Antikörper als Antidote

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties